[1]曹虹丽,彭廷云,陈青山,等.柴芍六君子汤对原发性肝癌患者化疗期间疗效及免疫功能的影响[J].陕西中医,2024,(11):1495-1498.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.011]
　CAO Hongli,PENG Yanyun,CHEN Qingshan,et al.Effect of Chaishao Liujunzi decoction on therapeutic effect and immune function of primary liver cancer during chemotherapy[J].,2024,(11):1495-1498.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.011]
点击复制

柴芍六君子汤对原发性肝癌患者化疗期间疗效及免疫功能的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年11期
页码:
1495-1498
栏目:
临床研究
出版日期:
2024-11-05

文章信息/Info

Title:
Effect of Chaishao Liujunzi decoction on therapeutic effect and immune function of primary liver cancer during chemotherapy
作者:
曹虹丽; 彭廷云; 陈青山; 谢小芳; 王理槐; LAU Yuhao(马来西亚)
(湖南中医药大学第一附属医院肿瘤科,湖南 长沙 410007)
Author(s):
CAO Hongli; PENG Yanyun; CHEN Qingshan; XIE Xiaofang; WANG Lihuai; LAU Yuhao
(Department of Oncology,the First Hospital of Hunan University of Chinese Medicine,Changsha 410007,China)
关键词:
原发性肝癌;  柴芍六君子汤;  干扰素-γ;  白细胞介素-2;  生存率;  下肢浮肿
Keywords:
Primary liver cancer;  Chaishao Liujunzi decoction;  Interferon-γ;  Interleukin-2;  Survival rate;  Lower extremity edema
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2024.11.011
文献标志码:
A
摘要:
目的:观察柴芍六君子汤用于原发性肝癌患者化疗的效果及随访情况。方法:选取106例原发性肝癌患者纳入研究,按抽签法分为观察组、对照组,各53例。对照组采用FOLFOX4方案化疗,观察组在化疗基础上服用柴芍六君子汤治疗。记录两组患者疗效及不良反应,比较两组患者中医证候积分、Th1/Th2细胞因子谱变化及治疗6个月后随访情况。结果:观察组客观反应率高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者上腹胀满、倦怠短气、下肢浮肿、大便溏数的评分下降,且观察组低于对照组,差异有统计学意义(均P<0.05)。治疗后两组患者血清干扰素-γ(IFN-γ)、白细胞介素-2(IL-2)上升,白细胞介素-4(IL-4)、白细胞介素-10(IL-10)下降,且观察组改变程度高于对照组,差异有统计学意义(均P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。随访6个月,观察组生存率为92.45%,对照组生存率为83.12%,组间比较差异无统计学意义(P>0.05)。结论:柴芍六君子汤用于原发性肝癌化疗能减轻患者症状,提高免疫功能,且安全性较好。
Abstract:
Objective:To observe efficacy and follow-up of Chaishao Liujunzi decoction in patients with primary liver cancer during chemotherapy.Methods:106 patients with primary liver cancer were selected for study.Patients were divided into observation group and control group by drawing lots,with 53 cases in each group.The control group received chemotherapy with FOLFOX4 regimen,while the observation group treated with Chaishao Liujunzi decoction on the basis of chemotherapy.Record therapeutic effects and adverse reactions of the two groups,and traditional Chinese medicine syndrome scores,Th1/Th2 cytokine levels,and follow-up after 6 months of treatment between the two groups were compared.Results:The objective response rate of the observation group were higher than that in the control group,difference statistically significant(P<0.05).After treatment,the scores of upper abdominal swelling,fatigue and shortness of breath,lower limb edema and loose stools significantly decreased in both groups,and the observation group lower than the control group,difference statistically significant(all P<0.05).After treatment,serum level of IFN-γ,IL-2 in two groups significantly increased,while IL-4,IL-10 significantly decreased,degree of change in the observation group were higher than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Follow up for 6 months showed survival rate of 92.45% in the observation group and 83.12% in the control group.There was no significant difference between the two groups(P>0.05).Conclusion:Chaishao Liujunzi decoction has significant therapeutic effect on patients with primary liver cancer during chemotherapy,which can alleviate symptoms,improve immune function,and security was better.

参考文献/References:

[1] LI C,HE W Q.Comparison of primary liver cancer mortality estimates from world health organizationglobal burden disease and global cancer observatory[J].Liver International:Official Journal of the International Association for the Study of the Liver,2022,42(10):2299-2316.
[2] 陈倩倩,芮法娟,倪文婧,等.原发性肝癌的流行病学及其危险因素研究进展[J].中国全科医学,2024,27(6):637-642.
[3] XU W,ZHU Z,YU J,et al.Symptoms experienced after transcatheter arterial chemoembolization in patients with primary liver cancer:A network analysis[J].Asia Pacific J of Oncology Nursing,2024,11(3):100361.
[4] LIN P Z,HUANG B D,ZOU G X,et al.Percutaneous microwave ablation and transcatheter arterial chemoembolization for serum tumor markers and prognostics of middle-late primary hepatic carcinoma[J].World Journal of Gastrointestinal Surgery,2023,15(12):2783-2791.
[5] 惠友谊,薛敬东,高改娅,等.原发性肝癌中医证型及证素的文献研究[J].世界中医药,2023,18(3):401-405.
[6] 蒙健林,李飞燕,王明刚.原发性肝癌发病机制与中医“虚瘀劫肝”的关系[J].海南医学,2024,35(3):434-437.
[7] 王济国,黄洪疏,林丽珠.中西医结合治疗原发性肝癌的研究进展[J].世界复合医学,2023,9(6):183-186.
[8] 范震.柴芍六君子汤防治原发性肝癌肝动脉化疗栓塞术后栓塞综合征临床研究[J].河南中医,2022,42(11):1695-1699.
[9] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].肿瘤,2009,29(4):295-304.
[10] 吴煜,徐桂林,楼敏,等.中医药治疗原发性肝癌研究进展[J].人民军医,2011,54(6):527-528.
[11] 赵楷波,陈达满,陈正义,等.中医药结合化疗治疗原发性肝癌研究进展[J].中西医结合肝病杂志,2024,34(1):93-96.
[12] 王悦华,刘永雄.原发性肝癌的分期、根治切除标准及预后指标[J].中华肝胆外科杂志,2003,9(1):3-7.
[13] LIU D L,DONG M S,LI Y Y,et al.A clinical study of targeted immunotherapy combined with hepatic arterial chemoembolization in the treatment of liver injury associated with primary liver cancer[J].Chinese J of Hepatology,2023,31(11):1156-1162.
[14] LEI W,KUN H,YU Z,et al.Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma.[J].World J of Gastrointestinal Surgery,2023,15(1):105-113.
[15] XU J Y,SHAN Y,ZHANG C X,et al.Effect of Chinese medicines combined with transarterial chemoembolization on primary hepatic carcinoma:A systematic review and meta-analysis[J].Medicine,2023,102(26):e34165
[16] 邱汉波,赵艺蔓,周尧红,等.柴芍六君子汤联合经肝动脉栓塞化疗治疗原发性肝癌效果的Meta分析[J].中国当代医药,2021,28(10):20-22,27.
[17] 李翔,张领兄,张红.柴芍六君子汤加味治疗肝癌伽玛刀治疗后肝损伤临床观察[J].中医药临床杂志,2020,32(1):103-107.
[18] 邓鹏,徐驲,刘言薇,等.茯苓水提物对环磷酰胺荷瘤小鼠免疫微环境的影响[J].中国全科医学,2021,24(2):s28-s30.
[19] 陈叶青,李晓琳,陈子睿,等.基于数据挖掘的结直肠癌中医证型与中药应用规律研究[J].中国中医基础医学杂志,2022,28(3):412-416.
[20] 汪娟,王芳.白芍总苷治疗自身免疫性疾病的研究进展[J].医学综述,2021,27(22):4481-4485.
[21] 熊传锋,齐杰莹,邓蓉,等.白芍总苷抑制小鼠T淋巴细胞体外增殖促进活化诱导细胞死亡[J].南方医科大学学报,2020,40(1):118-124.
[22] 陈冬梅,蒙洁,刘佳佳,等.基于网络药理学的党参增强免疫功能机制研究[J].中华中医药学刊,2020,38(2):184-187.
[23] 夏召弟,马若昕,王凤云,等.党参免疫调节活性及其机制的研究进展[J].中草药,2023,54(13):4334-4345.
[24] 杨宇婷,曾柏荣.柴芍六君子汤治疗原发性肝细胞癌TACE术后患者肝损害的临床观察[J].云南中医中药杂志,2022,43(6):28-30.
[25] 高改娅,薛敬东,白艳艳,等.柴芍六君子汤加减治疗慢性胃炎效果与安全的Meta分析[J].中国医药导报,2020,17(11):140-144,156.

相似文献/References:

[1]乔喜婷,王 昊△,杨 林,等.复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌临床研究*[J].陕西中医,2019,(8):998.
　QIAO Xiting,WANG Hao,YANG Lin,et al.Fuyuan Huoxue decoction plus Huaji pills and hepatic artery embolization in the treatment of primary liver cancer[J].,2019,(11):998.
[2]李 丹,赵 飞,王树庚.疏肝健脾散结汤联合肝动脉插管化疗栓塞术治疗原发性肝癌疗效研究[J].陕西中医,2021,(6):728.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.012]
　LI Dan,ZHAO Fei,WANG Shugeng.Effect of Shugan Jianpi Sanjie decoction combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J].,2021,(11):728.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.012]
[3]赵培西,许建秦,袁 彬,等.扶正抗癌方治疗肝癌肝郁脾虚瘀毒证临床研究[J].陕西中医,2022,(12):1746.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.022]
[4]周 林,肖 康,夏建辉.八珍汤加减辅助治疗原发性肝癌疗效及对患者外周血Th17/Treg平衡和不良反应的影响[J].陕西中医,2023,(9):1216.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.013]
　ZHOU Lin,XIAO Kang,XIA Jianhui.Effect of modified Bazhen decoction adjuvant therapy on peripheral blood Th17/Treg balance and adverse reactions in patients with primary liver cancer[J].,2023,(11):1216.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.013]
[5]徐巧笑,胡振斌,莫莎莎,等.从“虚、毒、瘀”浅谈原发性肝癌病机和治疗[J].陕西中医,2023,(10):1431.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.022]
　XU Qiaoxiao,HU Zhenbin,MO Shasha,et al.Discussion on pathogenesis and treatment of primary liver cancer from the perspective of “deficiency,poison,and blood stasis”[J].,2023,(11):1431.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.022]
[6]吉 银,戴 铭,王振常,等.逍遥散合大黄虫丸治疗原发性肝癌经肝动脉化疗栓塞术后气滞血瘀型疗效研究[J].陕西中医,2024,(2):187.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.008]
　JI Yin,DAI Ming,WANG Zhenchang,et al.Treatment of primary hepatocellular carcinoma qi stagnation and blood stasis type patients after TACE with Xiaoyao San combined with Dahuang Zhechong pill[J].,2024,(11):187.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.008]
[7]邹勇斌,朱 莹.名中医朱莹基于“木郁达之”理论论治功能性腹胀[J].陕西中医,2024,(2):253.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.023]
[8]李俊漪,徐 剑.龙胆泻肝汤对原发性肝癌肝动脉栓塞化疗术后患者肝功能及肿瘤标志物的影响研究[J].陕西中医,2024,(10):1353.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.012]
　LI Junyi,XU Jian.Longdan Xiegan decoction on liver function and tumor markers in patients with PHC after TACE[J].,2024,(11):1353.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.012]

备注/Memo

备注/Memo:
基金项目:湖南省自然科学基金资助项目(2022JJ40330)
更新日期/Last Update: 2024-11-11